Clinical trial NCT05728736: Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
Official title: Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Alzheimer Disease
Keywords: poor sleep
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
Collaborators: name: Eisai Inc.
First posted: 2023-02-15
Enrollment: 0
Sex: ALL
Minimum age (years): 60
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study will look at the effects of lemborexant on Alzheimer's disease biomarkers found in the cerebrospinal fluid (CSF) and blood in individuals who are poor sleepers

Detailed description: This study will determine the acute effect of lemborexant on CNS tau phosphorylation and other Alzheimer's disease biomarkers in individuals with poor sleep quality.

Eligibility criteria: Inclusion Criteria:

* Age 60-80 years
* Any sex
* Any race/ethnicity
* Mini-Mental Status Examination score (MMSE) ≥ 27
* Positive plasma amyloid-beta test (i.e., amyloid-positive)
* Pittsburgh Sleep Quality Index \>5

Exclusion Criteria:

* Cognitive impairment as determined by history of MMSE \< 27
* Inability to speak or understand English
* Any sleep disorders other than insomnia
* No history of moderate-to-severe sleep-disordered breathing and STOP-Bang score \> 5
* History or reported symptoms suggestive of restless legs syndrome, narcolepsy or other sleep disorders
* No more than mild sleep apnea (AHI \<16) on PSG
* Sleep schedule outside the range of bedtime 22:00-midnight
* Contraindication to lumbar catheter (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery)
* Cardiovascular disease requiring medication except for controlled hypertension (PI discretion)
* Stroke
* Hepatic or renal impairment
* Pulmonary disease (PI discretion)
* Type 1 diabetes
* HIV or AIDS
* Neurologic or psychiatric disorder requiring medication (PI discretion)
* Suicidal ideations
* Alcohol, tobacco or marijuana use (PI discretion)
* Use of sedating medications (PI discretion)
* Inability to get out of bed independently
* In the opinion of the investigator, the participant should be excluded due to an abnormal physical examination.
* Current pregnancy
* Body Mass Index \>35
* History of migraines (PI discretion)
* History of drug abuse in the last 6 months
* History or presence of any clinically significant medical condition, behavioral or psychiatric disorder (including suicidal ideation), or surgical history based on medical record or patient report that could affect the safety of the subject or interfere with study assessments or in the judgment of the PI participant is not a good candidate.
* Urinary or fecal incontinence
* Concurrently enrolled in another trial of an investigational drug or device

Primary outcomes:
measure: Change in CNS tau phosphorylation
timeFrame: 48 hours
Secondary outcomes:
measure: Changes in other CSF AD biomarkers
timeFrame: 48 hours
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Brendan Lucey, MD
role: PRINCIPAL_INVESTIGATOR
References: